CD91:F:F-Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 32.235

Change

+0.47 (+1.46)%

Market Cap

USD 0.31B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 108.00B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-1.25 (-2.39%)

USD 105.67B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-1.48 (-2.56%)

USD 104.83B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.39 (-2.49%)

USD 62.86B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 49.04B
XJSE:F Xtrackers II - Japan Governmen..

N/A

USD 41.48B
0ZC:F Zscaler Inc

-3.58 (-1.84%)

USD 37.92B
BSND:F Danone SA

+0.10 (+0.74%)

USD 33.83B
VGWL:F Vanguard FTSE All-World UCITS ..

N/A

USD 24.77B

ETFs Containing CD91:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.41% 96% N/A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.41% 96% N/A 88% B+
Trailing 12 Months  
Capital Gain 54.90% 97% N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.90% 95% A 81% B-
Trailing 5 Years  
Capital Gain 69.12% 55% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 69.12% 55% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain 3.09% 43% F 48% F
Dividend Return 3.09% 41% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 19.38% 25% F 69% C-
Risk Adjusted Return 15.93% 34% F 43% F
Market Capitalization 0.31B 51% F 42% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.